Results 21 to 30 of about 14,657 (135)

Dosing of zoledronic acid with its anti-tumor effects in breast cancer

Journal of Bone Oncology, 2015
Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia.
Xinmin Zhao, Xichun Hu
doaj   +1 more source

Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog

Prostate Cancer, 2011
Background. Loss of bone density with androgen deprivation therapy for prostate cancer is well recognized. We assessed the effects of quarterly infusion of zoledronic acid on bone mineral density (BMD) and markers of bone turnover over a one-year period ...
Anoop Kapoor, Ankur Gupta, Nilay Desai, Hongshik Ahn   +3 more
doaj   +1 more source

Zoledronic acid in breast cancer: latest findings and interpretations

Therapeutic Advances in Medical Oncology, 2011
The intravenous nitrogen-containing bisphosphonate zoledronic acid has been shown to block multiple steps in tumor metastasis (e.g. angiogenesis, invasion, adhesion, proliferation) in preclinical and translational studies.
Michael Gnant
doaj   +1 more source

Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay

BMC Cancer, 2009
Previous data suggest that lipophilic statins such as fluvastatin and N-bisphosphonates such as zoledronic acid, both inhibitors of the mevalonate metabolic pathway, have anti-cancer effects in vitro and in patients.
Dexel Susanne, Reichelt Ralf, Fernando Augusta, Glaysher Sharon, Kurbacher Christian M, Knight Louise A, Reinhold Uwe, Cree Ian A   +7 more
doaj   +1 more source

Assessment of the Impact of Zoledronic Acid on Ovariectomized Osteoporosis Model Using Micro-CT Scanning. [PDF]

PLoS ONE, 2015
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic acid on the cancellous bone microstructure and its effect on the level of β-catenin in a mouse model of postmenopausal osteoporosis.96 8-week-old specific ...
Bo Shuai, Lin Shen, Yanping Yang, Chen Ma, Rui Zhu, Xiaojuan Xu   +5 more
doaj   +1 more source

Zoledronic acid and teriparatide have a complementary therapeutic effect on aseptic loosening in a rabbit model

BMC Musculoskeletal Disorders, 2021
Background Revisions are mainly caused by wear debris-induced aseptic loosening. How to effectively suppress debris-induced periprosthetic osteolysis has become an urgent problem.
Peng Wang, Guang-qian Shang, Shuai Xiang, Hai-ning Zhang, Ying-zhen Wang, Hao Xu   +5 more
doaj   +1 more source

Lessons learned from long-term side effects after zoledronic acid infusion following denosumab treatment: a case report and review of the literature

Journal of Medical Case Reports, 2022
Background Zoledronic acid is an intravenous, highly potent aminobisphosphonate for use in patients with primary or secondary osteoporosis. Zoledronic acid-induced prolonged side-effects are well known and quite common.
Ilona Nurmi-Lüthje, Peter Lüthje
doaj   +1 more source

Comprehensive evaluation of compound Kushen injection combined with zoledronic acid in treating bone metastasis cancer pain based on meta-analysis and decision tree model

Frontiers in Pain Research
ObjectiveTo evaluate the safety, efficacy, and cost-effectiveness of combining Compound Kushen Injection (CKI) with zoledronic acid in the treatment of bone metastasis-induced cancer pain in malignant tumors.MethodsA comprehensive search of Chinese and ...
Xi Zhao, Tianwei Meng, Kaiqiang Wang, Xi Yan, Yuqiang Liu, Xinghua Li   +5 more
doaj   +1 more source

Acute unilateral anterior uveitis following zoledronic acid infusion: A case report

SAGE Open Medical Case Reports, 2020
Bisphosphonates are widely used to treat several clinical conditions. Zoledronic acid is one of this class, commonly used for the treatment and prevention of osteoporosis, hypercalcemia of malignancy, Paget’s disease, and multiple myeloma.
Kiruththihan Anandasayanan, Muthusamy Malaravan, Navaneethakrishnan Suganthan   +2 more
doaj   +1 more source

Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review

Journal of Bone Oncology, 2015
Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor ...
Hampig Raphael Kourie, Joelle Antoun, Elie El Rassy, Marc Rassy, Claude Sader-Ghorra, Joseph Kattan   +5 more
doaj   +1 more source